» Articles » PMID: 19996211

Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2009 Dec 10
PMID 19996211
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

PURPOSE: CD44 is one of the most common markers used for identification of highly tumorigenic subpopulations of human carcinoma cells, but little is known about the function of CD44 or its major ligand, hyaluronan, in these cells. The purpose of this study was to investigate the involvement of hyaluronan and its interaction with CD44 in the properties of a tumorigenic subpopulation of primary ovarian carcinoma cells. EXPERIMENTAL DESIGN: A tumorigenic subpopulation was identified in ascites fluids from ovarian carcinoma patients by expression of high CD133 levels. Treatment with small hyaluronan oligosaccharides, which dissociate constitutive hyaluronan polymer-CD44 interactions, was used to test the importance of hyaluronan-CD44 interaction in assembly of multidrug and monocarboxylate transporters and receptor tyrosine kinases in the plasma membrane of cells with high CD133 levels, and in the tumorigenic capacity of the CD133-high subpopulation. RESULTS: Although total CD44 levels were similar in cells with high or low CD133 expression, CD44 was present in close association with transporters, receptor tyrosine kinases, and emmprin (CD147) in the plasma membrane of cells with high CD133 levels. Treatment with small hyaluronan oligosaccharides reduced association of the transporters and receptor tyrosine kinases with CD44 in the plasma membrane, diminished drug transporter activity, and inhibited i.p. tumorigenesis in these cells. CONCLUSIONS: We conclude that hyaluronan-CD44 interaction plays an important role in the properties of highly tumorigenic cells by stabilizing oncogenic complexes in their plasma membrane, and that treatment with hyaluronan-CD44 antagonists provides a logical therapeutic approach for abrogating the properties of these cells. (Clin Cancer Res 2009;15(24):7593-601).

Citing Articles

Lateral interactions between CD276 and CD147 are essential for stemness in breast cancer: a novel insight from proximal proteome analysis.

Seo Y, Lee J, Ryu H, Kim E, Kim S, Jeong J Sci Rep. 2023; 13(1):14242.

PMID: 37648771 PMC: 10469185. DOI: 10.1038/s41598-023-41416-7.


Therapeutic vulnerabilities of cancer stem cells and effects of natural products.

Reisenauer K, Aroujo J, Tao Y, Ranganathan S, Romo D, Taube J Nat Prod Rep. 2023; 40(8):1432-1456.

PMID: 37103550 PMC: 10524555. DOI: 10.1039/d3np00002h.


Hyaluronic Acid as a Modern Approach in Anticancer Therapy-Review.

Michalczyk M, Humeniuk E, Adamczuk G, Korga-Plewko A Int J Mol Sci. 2023; 24(1).

PMID: 36613567 PMC: 9820514. DOI: 10.3390/ijms24010103.


Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma.

Hua S, Viera M, Yip G, Bay B Cancers (Basel). 2023; 15(1).

PMID: 36612261 PMC: 9818616. DOI: 10.3390/cancers15010266.


Deregulated hyaluronan metabolism in the tumor microenvironment drives cancer inflammation and tumor-associated immune suppression.

Donelan W, Dominguez-Gutierrez P, Kusmartsev S Front Immunol. 2022; 13:971278.

PMID: 36238286 PMC: 9550864. DOI: 10.3389/fimmu.2022.971278.


References
1.
Miletti-Gonzalez K, Chen S, Muthukumaran N, Saglimbeni G, Wu X, Yang J . The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 2005; 65(15):6660-7. DOI: 10.1158/0008-5472.CAN-04-3478. View

2.
Yeo T, Nagy J, Yeo K, Dvorak H, Toole B . Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol. 1996; 148(6):1733-40. PMC: 1861653. View

3.
Bourguignon L, Gilad E, Peyrollier K . Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem. 2007; 282(27):19426-41. DOI: 10.1074/jbc.M610054200. View

4.
Shipitsin M, Polyak K . The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest. 2008; 88(5):459-63. PMC: 3702270. DOI: 10.1038/labinvest.2008.14. View

5.
Lopez J, Camenisch T, Stevens M, Sands B, McDonald J, Schroeder J . CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res. 2005; 65(15):6755-63. DOI: 10.1158/0008-5472.CAN-05-0863. View